ABIVAX Société Anonyme (EPA:ABVX)

Market Cap	8.59B +2,038.8%
Revenue (ttm)	5.31M -42.9%
Net Income	-293.52M
EPS	-4.46
Shares Out	77.83M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68,620
Average Volume	101,364
Open	111.20
Previous Close	110.40
Day's Range	108.20 - 112.60
52-Week Range	4.51 - 132.00
Beta	-0.42
RSI	60.91
Earnings Date	Mar 23, 2026

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 67
• Stock Exchange: Euronext Paris
• Ticker Symbol: ABVX

Financial Performance

In 2024, ABIVAX Société Anonyme's revenue was 10.79 million, an increase of 135.94% compared to the previous year's 4.57 million. Losses were -176.24 million, 19.3% more than in 2023.